Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women

What Was Tested

The paper reports a study of Oxytocin and Vasopressin, published as a randomized controlled trial.

Compounds that block uterine oxytocin and vasopressin V1a receptors have a therapeutic potential in preterm labor and primary dysmenorrhoea.

The orally active vasopressin V1a receptor antagonist, SR49059, inhibits the effect of vasopressin on human uterine activity in vivo, but the influence on the response to oxytocin is unknown.

Who Took Part

The age groups tagged for this paper are adults, women only.

Sixteen healthy female subjects, who had previously undergone sterilization with tubal ligation, participated in intrauterine pressure recordings at one of the first 3 days of bleeding of two menstrual cycles.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Oxytocin could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The area between the recording curve and zero level of intrauterine pressure (AUC) was calculated.

Vital signs as well as urine and plasma safety parameters were measured.

The plasma concentrations of oxytocin, vasopressin and the study drug were also estimated.

What Was Measured

Compounds that block uterine oxytocin and vasopressin V1a receptors have a therapeutic potential in preterm labor and primary dysmenorrhoea.

Topics PubMed links to this paper include Area Under Curve, Indoles, Oxytocin, Pyrrolidines, Uterine Contraction and Vasopressins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin and Vasopressin.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Acta obstetricia et gynecologica Scandinavica), a journal based in United States.

More context: the Oxytocin compound page and the Vasopressin compound page, all human trials.